ACC.24: Late-Breaking Science Video Collection

Published: 06 April 2024

  • Views:

    Views Icon 5943

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.

 

To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.

 

For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

 

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

More from this programme

Part 1

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24. 

2 sessions
ACC.24 Late-breaking Science Wrap Up Watch now
What's Hot at ACC.24? Late-breaking Science Preview Watch now

Part 2

Late-Breaker Discussion Series

Host, Dr Harriette Van Spall is joined by principal investigators for discussion on selected late-breaking trials.  

4 sessions
Late-Breaker Discussion: The EMPACT-MI Trial Watch now
Late-Breaker Discussion: The AEGIS-II Trial Watch now
Late-Breaker Discussion: The RELIEVE-HF Trial Watch now
Late-Breaker Discussion: The ARISE-HF Trial Watch now

Part 3

Expert Interviews

Expert Interviews conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

12 sessions
Gamification and Financial Incentives to Increase PA Among Patients at Elevated Cardiovascular Risk Watch now
Zilbesiran in Patients With Hypertension: KARDIA-2 Watch now
Olezarsen in Adults with Hypertriglyceridemia and ASCVD and/or Severe Hypertriglyceridemia Watch now
Lerodalcibep in Patients With High Risk For Cardiovascular Disease on Stable Lipid-Lowering Therapy Watch now
Chelation Therapy in Post-MI Pts with Diabetes: TACT2 Watch now
Semaglutide in Patients with HfpEF, Obesity and Diabetes: STEP HFpEF Watch now
Self-Expanding vs Balloon Expandable TAVR: The SMART Trial Watch now
Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT Watch now
Technology-Assisted Nonprescription Rosuvastatin: TACTiC Watch now
Coronary Sinus Reducer in Refractory Angina: ORBITA COSMIC Watch now
TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6 Watch now
Periprocedural Cerebral Embolisms and Catheter Ablation of AF: The Embo-Abl Study Watch now

Part 4

Highlights

2 sessions
Artificial Intelligence in Cardiology: What You Need to Know in 2024 Watch now
Weight Loss Medications: What You Need to Know in 2024 Watch now

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

1 session
Clinical Trials: Making a Difference & Advice for Early Career Researchers with Dr Kosiborod Watch now

About the episode

ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).

This multicenter, randomized, double-blind study included 152 participant with hypertriglyceridemia (triglycerides > 150mg/dL) and established or increased risk of ASCVD. The study involved an 8-week screening period, a 23-week treatment period and a 13-week follow-up period. Patients were randomized 1:1 to recieve either olezarsen adminstered by injection once every 4 weeks, or placebo.

Findings suggest that in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, 50mg or 80mg olezarsen monthly significantly reduced triglyceride levels, as well as meaningful reductions in apolipoprotein B and non-high-density lipoprotein cholesterol, both of which are markers of atherogenic risk.

Interview Questions: 

  1. What is the reasoning behind this study?
  2. Could you tell us the mechanism of action of olezarsen
  3. What was the patient population and study design?
  4. What are the key findings?
  5. What are the implications of these findings on clinical practice?
  6. Where are the knowledge gaps?
  7. What are the next steps?

Recorded onsite at the ACC Conference in Atlanta, 2024.

Faculty Biographies

Brian Bergmark

Associate Physician in Interventional Cardiology

View full profile

Comments

You must be to comment. If you are not registered, you can register here.